ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,637.70
0.06%
Dow Jones
41,488.19
1.65%
Gold vs US Dollar
2,986.42
-0.01%
Brent Oil
70.715
-0.07%
Bitcoin
83,334.49
0.95%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. OKYO Pharma Ltd (OKYO)

  7. OKYO Pharma Ltd (OKYO) News

OKYO Pharma (OKYO)

OKYO Pharma Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:OKYO
DateTimeSourceHeadlineSymbolCompany
10/03/202512:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
10/03/202512:30GlobeNewswire Inc.OKYO Pharma Files for Fast Track Designation with FDA for Urcosimod to Treat Neuropathic Corneal PainNASDAQ:OKYOOKYO Pharma Ltd
12/02/202512:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
12/02/202512:00GlobeNewswire Inc.OKYO Pharma Announces OK-101 Officially Assigned USAN : UrcosimodNASDAQ:OKYOOKYO Pharma Ltd
31/01/202512:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
31/01/202512:00GlobeNewswire Inc.OKYO Pharma Announces Chairman and CEO Acquire SharesNASDAQ:OKYOOKYO Pharma Ltd
29/01/202521:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
29/01/202513:00GlobeNewswire Inc.OKYO Pharma to Complete Enrollment of Neuropathic Corneal Pain Trial by End of Second QuarterNASDAQ:OKYOOKYO Pharma Ltd
22/01/202512:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
22/01/202512:00GlobeNewswire Inc.OKYO Pharma Receives $1.4 Million in Non-Dilutive FundingNASDAQ:OKYOOKYO Pharma Ltd
26/11/202412:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
26/11/202412:00GlobeNewswire Inc.OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology ConferenceNASDAQ:OKYOOKYO Pharma Ltd
30/10/202411:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
30/10/202411:00GlobeNewswire Inc.OKYO Pharma to Present at International Tear Film and Ocular Surface Society ConferenceNASDAQ:OKYOOKYO Pharma Ltd
23/10/202411:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
23/10/202411:00GlobeNewswire Inc.OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal PainNASDAQ:OKYOOKYO Pharma Ltd
16/10/202411:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
16/10/202411:00GlobeNewswire Inc.OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal PainNASDAQ:OKYOOKYO Pharma Ltd
10/09/202411:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
10/09/202411:00GlobeNewswire Inc.OKYO Pharma Announces Chairman Acquires SharesNASDAQ:OKYOOKYO Pharma Ltd
05/09/202411:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
05/09/202411:00GlobeNewswire Inc.OKYO Pharma Announces Chairman Acquires SharesNASDAQ:OKYOOKYO Pharma Ltd
27/08/202411:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
27/08/202411:00GlobeNewswire Inc.OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye DiseaseNASDAQ:OKYOOKYO Pharma Ltd
23/08/202413:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
23/08/202413:00GlobeNewswire Inc.OKYO Pharma CEO Interview to Air on Bloomberg TVNASDAQ:OKYOOKYO Pharma Ltd
23/08/202411:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
23/08/202411:00GlobeNewswire Inc.OKYO Pharma Announces Chairman Acquires SharesNASDAQ:OKYOOKYO Pharma Ltd
21/08/202411:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:OKYOOKYO Pharma Ltd
21/08/202411:00GlobeNewswire Inc.OKYO Pharma Announces Chairman Acquires SharesNASDAQ:OKYOOKYO Pharma Ltd
 Showing the most relevant articles for your search:NASDAQ:OKYO

Your Recent History

TSX
NB
NioCorp Developments
TG
56X
Vertex
TG
29Z
AgEagle Aerial Systems
TG
2OQ
Amplify Energy
TG
ER2
Emcore
TG
OIC
OCI NV
TG
KDB
KBC Groep NV
TG
S86
SPS Commerce
LSE
RTG
Rethink Group
TG
3K6
ESR
ASX
GRE
Greentech Metals
TSX
EXE
Extendicare
TG
VP2
Valeo Pharma
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads